AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02609386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc-containing multivitamin
Description: Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
Study NCT02609386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc-containing multivitamin
Description: Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
Study NCT02609386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Method of Administration: Omeprazole is administered orally for 21 days
Study NCT02609386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Method of Administration: Omeprazole is administered orally for 21 days
Study NCT04378595 — intervention group
Intervention type: OTHER
Intervention: During COVID-19 Pandemic
Description: Assessing status of food insecurity during the COVID-19 pandemic
Study NCT04378595 — intervention group
Intervention type: OTHER
Intervention: After COVID-19 Pandemic
Description: Assessing status of food insecurity after the COVID-19 pandemic
Study NCT02029482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Study NCT02029482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04630782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI scan
Description: Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
Study NCT02624635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
Study NCT02624635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Hip Strengthening
Description: It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ \[1.0278 - (0.0278 x number of repetitions)\] as was used by (Shirazi et al., 2007).
Study NCT03405168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Hydrochloride 400mg Tablet
Description: Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
Study NCT02640898 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: docetaxel-based chemoradiotherapy
Description: experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
Study NCT02640898 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FU-based chemoradiotherapy
Description: The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
Study NCT00459771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT1 blocker candesartan
Description: AT1 blocker candesartan, 32 mg oral QD
Study NCT00459771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 32 mg, oral QD
Study NCT03594799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed Rest Control Group
Description: Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.
Study NCT03594799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocktail intervention
Description: Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
Study NCT03019029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18-F Florbetapir PET/MR scan
Description: 18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
Study NCT02131233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated Raltegravir
Description: Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
Study NCT02131233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg tablet orally twice daily
Study NCT02131233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRUVADA™
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
Study NCT02131233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA™
Description: Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
Study NCT02131233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Reformulated Raltegravir
Description: Placebo to reformulated raltegravir 2 tablets orally once daily
Study NCT02131233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Raltegravir
Description: Placebo to raltegravir 1 tablet orally twice daily
Study NCT01818089 — intervention group
Intervention type: DEVICE
Intervention: Lung sound analyzer
Description: Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
Study NCT02535650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
Study NCT01869088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5 Injection
Description: After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery
Study NCT01869088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transartery Chemoembolization
Description: Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
Study NCT01869088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transartery Chemoembolization
Description: Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
Study NCT00383370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: VEGF Trap formulation 1, ITV-1
Study NCT00383370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap
Description: VEGF Trap formulation 2 at higher concentration in Open label cohort
Study NCT02957617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
Study NCT00817388 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03147950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone-Flexed PCNL
Description: Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
Study NCT03147950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone PCNL
Description: Prone Position For Percutaneous Nephrolithotomy (PCNL)
Study NCT03301077 — intervention group
Intervention type: OTHER
Intervention: 2-phase epidemiological study (screening, interviews)
Description: first phase is the screening phase, second phase is the interview phase
Study NCT02149563 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: oxygen-enriched air -Normobaric hyperoxia treatment for depression
Description: Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
Study NCT02149563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen-enriched air -Normobaric hyperoxia treatment for depression
Description: Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
Study NCT01825746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of the MOHR assessment in primary care workflow
Description: The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
Study NCT01825746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of the MOHR assessment in primary care workflow
Description: The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
Study NCT02710019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back to Reality Series Video Games
Description: Back to Reality Series are a psycho-educational video games that provide information about psychosis and marijuana use from the perspective of 'Harry': a character who experiences problems with both issues. The aim is for players to learn how to detect some signs of psychosis and where to seek help for mental health and addictions problems.
Study NCT02710019 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Video Game
Description: The control video game consists of digital puzzles and spelling game about pop culture. The control games does not have any content related to mental health and addictions problems
Study NCT02311608 — intervention group
Intervention type: DRUG
Intervention: Terlipressin
Description: administered as a first-line medicine or as salvage
Study NCT02311608 — intervention group
Intervention type: DRUG
Intervention: Usual Dose Somatostatin/Octreotide
Description: administered as a first-line medicine or as salvage
Study NCT02311608 — intervention group
Intervention type: DRUG
Intervention: High Dose Somatostatin/Octreotide
Description: administered as salvage
Study NCT02117609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New DELICAL formula
Description: 3 months with the option of continuing until 6 months.
Study NCT02117609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard DELICAL formula
Description: 3 months with the option of continuing until 6 months.
Study NCT00177866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks.
Study NCT00177866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo PO BID for either the first eight weeks or the last eight weeks of the study.
Study NCT03247322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication therapy using mHealth application
Description: This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
Study NCT03440138 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery (RYGB or SG)
Description: laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
Study NCT03785314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization with different posture
Study NCT02210507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified cassava gari
Description: Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
Study NCT02210507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White cassava gari
Description: Non-biofortified (white) cassava and a retinyl palmitate reference dose.
Study NCT02210507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White cassava gari + red palm oil
Description: Non-biofortified (white) cassava gari containing red palm oil.
Study NCT04399889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.
Description: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.
Study NCT04399889 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.
Study NCT05644678 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliances
Description: Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.
Study NCT05644678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.
Study NCT03886584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring source test
Description: Internal- and external-monitoring correct responses and inversions
Study NCT03886584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring source test
Description: Internal- and external-monitoring correct responses and inversions
Study NCT01537835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial Scrubs
Description: Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
Study NCT00926341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Tab. Pioglitazone-30 mg/day, oral, 24 weeks
Study NCT00926341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Tab. Telmisartan- 40 mg/day, oral, 24 weeks
Study NCT02163681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Helium-3 MRI of the chest
Description: hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
Study NCT02072941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE Intervention
Description: At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
Study NCT01996150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleach bath (sodium hypochlorite)
Description: Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
Study NCT01254656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
Study NCT01254656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
Study NCT01254656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
Study NCT01254656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
Study NCT01254656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lersivirine
Description: Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
Study NCT01254656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etravirine
Description: Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
Study NCT00412789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Study NCT02119078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute Care of Elders focused geriatric care
Description: Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
Study NCT01067417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Taken orally 2x200mg capsules once daily for 48 weeks
Study NCT01067417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken orally 2x200mg capsules once daily for 48 weeks
Study NCT02196857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
Study NCT02196857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
Study NCT02589509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct-attention training using web-based BrainHQ
Description: BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame.
Study NCT02589509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Description: A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.